CAMBRIDGE, Mass., July 16, 2025 - Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company focused on developing innovative genetic therapies, has announced a significant boost in funding with up to $24 million from the Cystic Fibrosis Foundation (CF Foundation). This additional investment aims to accelerate the development of Prime Editors, which are designed to permanently correct cystic fibrosis-related lung disease. The funding will be provided in two tranches, contingent on certain closing conditions and scientific milestones. Prime Medicine plans to initially target the G542X mutation, a prevalent CF-causing nonsense mutation with no current therapies available. The CF Foundation's commitment underscores its confidence in Prime Editing as a transformative approach for cystic fibrosis, with the potential to treat a majority of those affected by the disease. This funding is a continuation of the support established in a January 2024 agreement and highlights the strategic collaboration between Prime Medicine and the CF Foundation to drive innovative solutions for cystic fibrosis.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.